Medtronic Inc's Resolute Integrity Drug-Eluting Stent Obtains FDA Approval For Treating Coronary Artery Disease

Medtronic, Inc. announced U.S. Food and Drug Administration (FDA) approval of the Resolute Integrity Drug-Eluting Stent (DES) for the treatment of coronary artery disease (CAD). The new heart device`s FDA approval stems from the results of a global series of studies involving the Resolute DES, which showed consistently clinical performance across a broad spectrum of patients -- including those with diabetes, a common contributor to coronary artery disease that complicates treatment. The Resolute DES uses the same drug-and-polymer combination as the Resolute Integrity DES.